Early growth response 1 (EGR1) is a nuclear transcriptional factor that belongs to a family of early response genes[@b1]. It contains a highly conserved DNA-binding domain that binds to the GC-rich consensus sequence GCG (G/T) GGGCG[@b2][@b3][@b4]. Its promoter contains several important elements, such serum response elements (SREs), cAMP response element(CRE), nuclear factor binding domains, and EGR1 binding site(EBS), to provide a negative feedback loop for controlling EGR1 expression[@b5][@b6][@b7]. Multiple factors stimulate the transcription of the EGR1 gene, such as growth factors, cytokines, UV, and hypoxia[@b7][@b8]. EGR1 gene expression is mediated through subgroups of MAPKs, including ERK, JNK, and p38 pathways[@b9][@b10].

EGR1 is crucial in the development of various carcinomas with opposing biofunctions. Some reports regard the gene to be a positive impact factor in prostate cancer[@b11]. Recent studies have described EGR1 as a tumor repressor that directly or indirectly upregulates multiple tumor suppressors, including PTEN, TP53, fibronectin, BCL-2, and TGFβ1, to inhibit cell growth, proliferation, and metastasis, as well as induce apoptosis[@b12].

We surmised that the positive and negative functions of EGR1 in tumor development relied on the integrated result of its gene regulation functions. A previous study summarized the functions of all known and putative target genes of EGR1 in proliferation/transforming, survival/differentiation, apoptosis, tumor progression/angiogenesis, and grown inhibition in different cells or tissues[@b8]. Many studies showed the evident correlation between EGR1 and PTEN expression. PTEN activation was an important tumor-suppressing process that required p14ARF-mediated EGR1 sumoylation, which contributed to the Akt-EGR1-ARF-PTEN axis and stimulated growth or apoptosis[@b13]. PTEN was shown to be mutated or deleted in many types of prostate tumors, disabling its tumor-suppressing function in carcinoma development regardless of EGR1 expression[@b14]

Ferraro et al.[@b15] reported that EGR1 was underexpressed in non-small cell lung carcinoma (NSCLC) than in normal lung tissue and low EGR1 expression was predictive of poor survival regardless of tumor stage in a stratified log-rank test. In vitro assays performed in the present study confirmed that EGR1 was able to arrest lung cancer cell mobility and induce cell apoptosis. Microarray and bioinformatic analyses were applied to characterize the direct or indirect target genes of EGR1 and provided a general view of the functions of EGR1 in NSCLC. We further confirmed by the testing of clinical samples that the promoter of KRT18 contained EGR1 binding sites and KRT18 expression was directly regulated by EGR1, contributing to decrease malignancy of NSCLC.

Results
=======

Upregulation of EGR1 decreases NSCLC proliferation in vitro
-----------------------------------------------------------

Basing on the report of Ferraro et al.[@b15] that EGR1 was underexpressed in NSCLC compared with that in normal lung tissue, we detected the expression level of EGR1 in several lung cancer cell lines. EGR1 was highly expressed in giant cell lung carcinoma cell line 95D, but it was not significantly different among the NSCLC cell lines H1299 and H358 and human fetal lung fibroblast cell line MRC5. EGR1 expression was clearly undetectable by western blot assay in the human adenocarcinoma cell line A549 ([Fig. 1A](#f1){ref-type="fig"}). The results indicated that EGR1 was not upregulation in most lung cancer cell lines.

We evaluated cell proliferation rate by infecting lentiviral vector CD513B-1-EGR1 or dnEGR1 (dominant negative EGR1, EGR1 inhibitor)[@b16][@b17] in H1299 cells to determine whether EGR1 had a negative effect on cell growth. Compared with the mock control, the cells with EGR1 had significantly lower growth rate, whereas the cells with dnEGR1 had no significant difference in cell proliferation ([Fig. 1C](#f1){ref-type="fig"}). Therefore, CDK family members CDK2 and CDK6 were detected to show the inhibition of EGR1 on tumor cell growth. CDK2 was almost the same between the mock control and EGR1-overexpressing H1299 cells, while CDK6 in EGR1-overexpressing cells was significantly lower than control ([Supplementary Fig. S2A](#s1){ref-type="supplementary-material"}).

Further study using H1299 cells showed that EGR1 induced cell apoptosis at a rate of 25% relative to the mock control ([Fig. 1D](#f1){ref-type="fig"}). We then detected the caspase signals in the EGR1 induced H1299 cells. An evident increase in the activity of cleaved-caspase-3 and -7 was observed in the EGR1-overexpressing H1299 cells as compared with the mock control in an EGR1 dose-dependent manner ([Fig. 1E](#f1){ref-type="fig"}).

EGR1 upregulation decreases NSCLC migration in vitro
----------------------------------------------------

Wound-healing and migration assays were performed to evaluate the effect of EGR1 on cancer cell metastasis. In the wound-healing assay, EGR1 dramatically decreased cell mobility in both H1299 and A549 cells within 72 h as compared with the mock control. No significant difference was observed in the dnEGR1 group of H1299 and A549 cells at the same treatment period ([Fig. 2A](#f2){ref-type="fig"}). In the migration assay, EGR1 decreased the movement of the lung cancer cells. The EGR1-positive group showed a decreased migration by 41% and 50% in the H1299 and A549 cells, respectively (P \< 0.01), relative to control. By contrast, the dnEGR1 group showed no significant difference in cell migration rate in both lung cancer cell lines ([Fig. 2B](#f2){ref-type="fig"}). These results suggested that EGR1 arrested cell movement.

Genes differentially expressed in EGR1-overexpressing NSCLC cells
-----------------------------------------------------------------

The specific functions of EGR1 as a tumor suppressor in NSCLC were explored by determining the differentially expressed genes in the EGR1-overexpressed group and mock control group of H1299 cells. Gene expression profiles were obtained by microarray analysis using Affymetrix GeneChip PrimeView™ human gene expression arrays of 48937 probes. A total of 100 genes were identified as significantly differentially expressed in EGR1-overexpressing cells (ratio ≥ 2.0 or ≤0.5) ([Fig. 3A](#f3){ref-type="fig"}). 76 upregulated genes (76%) and 24 downregulated genes (24%) were detected in EGR1-overexpressing cells as compared with control ([Supplementary Table S3](#s1){ref-type="supplementary-material"}). A visualization of the differential expression pattern of the 100 genes is shown in [Fig. 3](#f3){ref-type="fig"} through a hierarchical clustering heat map. IPA launches revealed the bio-function enrichment profiles of these genes ([Fig. 3C](#f3){ref-type="fig"}). Terms closely related to cellular growth and proliferation, cellular movement, and gene expression were also found ([Supplementary Tables S4 to S6](#s1){ref-type="supplementary-material"}). Microarray data were validated by qPCR through the comparison of the expression levels of 14 randomly selected genes. The qPCR differential gene expression pattern in the EGR1-overexpressed cells was consistent with the microarray results ([Figs. 3B and 3D](#f3){ref-type="fig"}).

EGR1 influences cell growth and proliferation
---------------------------------------------

Many genes can influence cell growth by differential expression: (1) CDKN1C, CDC27, and PRKDC are regarded as cell cycle-related genes. CDKN1C expression increased up to 9.7-fold, whereas CDC27 and PRKDC decreased by 2.2- and 2.7-fold respectively. (2) CDKN1C, FGFR3, GDF15, HES1, LIF, DDIT3, and TOP1 are thought to arrest the growth of tumor cell lines. All these genes, except for TOP1, increased in expression in the EGR1-overexpressing cells. (3) FOS, GADD45B, RASD1, SERPINA1, SERTAD1, and VEGFA genes are attributed for colony formation of many different tumor cell lines, which were all upregulated in the experimental cell groups. (4) CD24, KCTD11, LIF, and TOP1, which contributes to growth inhibition or cytostasis, also demonstrated modified expression levels ([Table 1](#t1){ref-type="table"} and [Supplementary Table S3](#s1){ref-type="supplementary-material"}). The cell proliferation assay and cytometry analysis showed that EGR1 significantly inhibited cell growth ([Fig. 1C--E](#f1){ref-type="fig"} and [Supplementary Fig. S2A](#s1){ref-type="supplementary-material"}).

EGR1 regulates cellular movement
--------------------------------

Microarray results suggested that EGR1 may be involved in cellular movement and cell migration ([Table 1](#t1){ref-type="table"} and [Supplementary Table S5](#s1){ref-type="supplementary-material"}) by the following mechanisms: (1) GDF15, MMP9, ITGB8, and PDGFA alter tumor microenvironment interaction by modifying its cell adhesion ability; and (2) IL11, LIF, PDGFA, and VEGFA have cytokine-to-cytokine interaction ability that modify the epithelial--mesenchymal transition (EMT) in tumor cells. In the study, the cell migration assay results showed that EGR1 markedly arrested H1299 cell mobility ([Fig. 2](#f2){ref-type="fig"}). The phenomenon proofed the genes involved mobility or EMT played their roles in the EGR1 induced NSCLC cells.

EGR1 directly or indirectly regulates the expression of many genes
------------------------------------------------------------------

EGR1 is an important transcription factor that directly or indirectly regulates the expression of specific genes ([Table 1](#t1){ref-type="table"} and [Supplementary Table S6](#s1){ref-type="supplementary-material"}). Some of the genes regulated by EGR1 are (1) chromatin remodeling-associated genes (ID4, ID2, SOX8, HEYL, DEK, and C14orf106); (2) transcription regulation genes (RASD1, FOS, LEF1, NR4A1, and NKX2-2); and (3) translation-associated genes (SERTAD1 and SON).

KRT18 is regulated by EGR1 in NSCLC
-----------------------------------

Interestingly, the promoter of KRT18 (cytokeratin 18, also named CK18) was predicted to contain the EGR1 binding sites (EBS), at positions −115 to −101 (UCSC). The microarray results showed that KRT18 was upregulated approximately 3.5-fold by EGR1 induction. KRT18, together with KRT8 (CK8), is an extremely important tumor marker in clinical diagnosis that is expressed in single-layer epithelial tissues of the body and is involved in carcinogenesis[@b18][@b19]. The relationship between EGR1 and KRT18 was confirmed by dual luciferase assay. A series of deletion mutants of the KRT18 proximal promoter (−289 to +380) in the luciferase reporter vector were generated. Sequence analysis revealed that cells carried EBS demonstrated 2- to 5-fold luciferase activation in a dose-dependent manner, whereas the partial deletion of the EBS presented lower activity ([Fig. 4A](#f4){ref-type="fig"}). The complete deletion of EBS resulted in the mere induction of EGR1. To demonstrate that the EBS was indeed responsible for transactivation of the KRT18 promoter, the EBS were mutated (changed from GCGGGGGCG to TCGGTGGAT) in such a way that it no longer conformed with the consensus sequence for EGR1 binding. The reporter constructs became less transactivated in response to EGR1 transfection, confirming that the integrity of the EBS in the KRT18 promoter was essential for its expression by EGR1 ([Fig. 4B](#f4){ref-type="fig"}). The siRNAs that target EGR1 were used to knock down EGR1 in H1299 cells to further confirm the observed relationship between EGR1 and KRT18. After EGR1 was knocked down, the level of KRT18 notably decreased, indicating that the decreased in EGR1 decreased the KRT18 level ([Fig. 4C](#f4){ref-type="fig"}).

KRT18 is able to decrease the malignancy of NSCLC
-------------------------------------------------

As previously mentioned that EGR1 decreased tumorigenicity of NSCLC, and directly regulated KRT18, we supposed that KRT18 might also function as a tumor suppressor gene. Thus, we examined the characteristics of KRT18-overexpressed H1299 and A549 cells to test this possibility. We observed significant differences in the characteristics of the KRT18-overexpressed cells and control cells. The overexpression of KRT18 decreased the proliferation and migration ([Fig. 5A, 5B and 5C](#f5){ref-type="fig"}) of H1299 and A549 cells. Western blot showed that CDK6 expression was lower in KRT18-ovexpressed H1299 cells ([Supplementary Fig. S2B](#s1){ref-type="supplementary-material"}). Moreover, we tested increased activity of cleaved-caspase-3 and -7 in KRT18-overexpressed H1299 cells ([Fig. 5D](#f5){ref-type="fig"}). These results suggested that KRT18 acted as a tumor suppressor and decreased the tumorigenicity of NSCLC cells.

Correlations of the EGR1 and KRT18-positive expression with clinicopathological features were also studied in 36 NSCLC. [Fig. 5E](#f5){ref-type="fig"} confirmed the relationship between EGR1 and KRT18 in primary NSCLC cases. NSCLC tissues with EGR1 (+) were also KRT18 (+) in 54.5% of primary NSCLC cases. KRT18 (−) NSCLC cases accounted for 80.0% of EGR1 (−) tissues (P = 0.0485, Fisher\'s exact test; [Fig. 5F](#f5){ref-type="fig"}, [Supplementary Table S2](#s1){ref-type="supplementary-material"}). We found that EGR1 (+) NSCLC was significantly associated with age (P = 0.0294, Fisher\'s exact test; [Fig. 5F](#f5){ref-type="fig"}, [Supplementary Table S2](#s1){ref-type="supplementary-material"}) and lymph node metastasis (P = 0.0265, Fisher\'s exact test; [Fig. 5F](#f5){ref-type="fig"}, [Supplementary Table S2](#s1){ref-type="supplementary-material"}). Furthermore, KRT18 (+) NSCLC was also significantly associated with lymph node metastasis (P = 0.0042, Fisher\'s exact test; [Fig. 5G](#f5){ref-type="fig"}, [Supplementary Table S2](#s1){ref-type="supplementary-material"}). The clinicalpathological results conformed our previous data that EGR1 was able to decrease NSCLC malignancy through KRT18.

Discussion
==========

The function of EGR1 in tumor growth and development has been recently widely investigated. EGR1 was downregulated in neoplasia and various tumor cell lines[@b20]. Conversely, the constitutive expression of EGR1 resulted in the suppression of tumor cell growth and transformation[@b21]. In our present study, the function of EGR1 and its regulated genes were investigated in NSCLC cells. Two lung cancer cell lines H1299 and A549 decreased in cell mobility and migration with the overexpression of EGR1; EGR1 also induced H1299 NSCLC cell apoptosis.

Several differentially expressed genes affected cell growth and proliferation. Particularly, the cell cycle-related gene CDKN1C, also named p57 Kip2[@b22], was upregulated by almost up to 9-fold in the EGR1-overexpressing H1299 cells. CDKN1C is a potent, tight-binding inhibitor of several G1 cyclin/CDK complexes and, to a lesser extent, of the mitotic cyclin B-CDC2[@b23]. CDKN1C is a negative regulator of cell proliferation that may be involved in the maintenance of the non-proliferative state of the cell throughout its life cycle and consequently may also function as a tumor repressor[@b24]. CDC27 is another cell cycle-related gene that encodes for a cell cycle-regulated E3 ubiquitin ligase, which controls the progression of a cell throughout mitosis and the G1 phase of the cell cycle[@b25]; this gene also decreased in expression in the EGR1-overexpressing H1299 cells. GADD45B is a tumor suppressor gene that belongs to a group of genes previously shown to have increased transcript levels with stressful cell growth arrest[@b26][@b27]. In the present study, GADD45B demonstrated increased mRNA levels in the EGR1-overexpressing H1299 cells. Several anti-apoptotic proteins, such as SON[@b28], PRKDC[@b29], and TOP1[@b30], were also downregulated in the EGR1-overexpressing cells, and several apoptotic proteins, including KRT18[@b31], NR4A1[@b32], and TGM2[@b33], were upregulated in the same group of cells.

The current paper is the first to report that EGR1 directly regulates KRT18 expression. KRT18 is a very important tumor marker for clinical diagnosis; it encodes for the type I intermediate filament chain keratin 18, modulates intracellular signaling, and operates in conjunction with various related proteins[@b18]. KRT18 may affect carcinogenesis through several signaling pathways, such as PI3K/Akt, Wnt, and ERK MAPK. KRT18 but not KRT8 was demonstrated to act as a substrate for caspase digestion at two distinct sites (Asp238 and Asp396) during the intermediate stage of apoptosis, thereby serving as a marker for apoptosis, mainly by the activation of caspase-3, -6, and -7[@b34][@b35][@b36].

In the present study, we only established EGR1 directly regulated KRT1 expression; however, other 99 genes were also identified to have modified expression levels with EGR1 induction. These findings strongly support that EGR1 functions as an indirect tumor repressor through the targeting of anti-oncogenes and may contribute in the development of a target in NSCLC therapy.

Methods
=======

Cell lines and NSCLC tumor specimens
------------------------------------

Lung cancer cell lines (H1299, H358, A549, and 95D) and human fetal lung fibroblast cell line MRC5 were purchased from the American Type Culture Collection (Manassas, VA). Cells were maintained in 1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 10 mg/ml streptomycin. A total of 36 formalin-fixed and paraffin-embedded human NSCLC specimen slices were provided by Guangzhou Medical University Cancer Institute and Hospital (Guangzhou, China). Clinical data of patients included in this study are detailed in [Supplementary Table S1](#s1){ref-type="supplementary-material"}. No patients recruited in this study received any preoperative treatment.

Construction of recombinant vectors
-----------------------------------

The proximal promoter of KRT18 was amplified by PCR and cloned into pGL3-basic vector (Promega, USA). The EGR1 and KRT18 sequence was amplified, and the products were cloned into pcDNA3.1 (Invitrogen, USA) at the EcoRI and HindIII restriction sites. The competitive EGR1 domain dnEGR1 (dominant negative EGR1) sequence was cloned into pCMV-3xFLAG (Sigma--Aldrich, USA) through the assistance of Professor Mingtao Li of Sun Yat-Sen University. Lentiviral vector CD513B-1 was kindly supported by Professor Xinyuan Guan of The University of Hong Kong. EGR1, dnEGR1 and KRT18 were cloned into CD513B-1 at the EcoRI and NotI restriction sites. Transient recombinant cells were obtained by the transfection of the recombinant vector or empty vector through the use of Lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer\'s instructions Stably recombinant cells were obtained according to the common lentiviral packing and infection instructions. The total amount of DNA was normalized using an empty vector. Cell transfection assays were performed in duplicate and repeated at least three times.

RNA extraction and real-time quantitative PCR
---------------------------------------------

Cells were sub-cultured in a six-well plate (5 × 10^5^/well), transfected with empty or recombinant vectors after 24 h, and cultured for 48 h. Total RNA was isolated using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer\'s instructions. First-strand cDNA was synthesized using a first-strand reverse transcription kit (TOYOBO, Japan), and quantitative PCR (qPCR) reaction was performed on a Rotor-Gene 6000 (Corbertt, USA) with SYBR Green Dye mix (TAKARA, Japan). PCR amplification parameters were programmed as follows: 40 cycles of 94°C for 15 s, 60°C for 15 s, and 72°C for 15 s. The results were normalized to the relative amounts of 18s, and calculation was done by the comparative C~T~ method (ΔΔ C~T~ method).

Immunohistochemical staining
----------------------------

Immunohistochemical staining was performed using the standard streptavidin--biotin--peroxidase complex method. Briefly, paraffin block sections of squamous carcinomas were deparaffinized and rehydrated, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 20 min. Antigen retrieval was performed by heating the slides in a microwave oven for 10 min in 10 mmol/L citrate buffer at pH 6.0. Non-specific binding was blocked with 10% normal rabbit serum for 10 min at room temperature. Sections were incubated with rabbit anti-human EGR1 polyclonal antibody (Abgent, USA) at a dilution of 1∶500 at 4°C overnight. Bovine serum albumin (1%) diluted in PBS was included as a negative control. The slides were briefly washed, applied with biotinylated goat anti-rabbit immunoglobulin at 1∶100 concentration, and then incubated at 37°C for 30 min. The slides were subsequently incubated with streptavidin--peroxidase conjugate for 45 min at room temperature and developed with diaminobenzidine tetrahydrochloride. The status of the cytoplasmic and nuclear expression of EGR1 was assessed by three independent investigators without previous knowledge of clinicopathological data. A positive result was defined in the present study as the detection of three or more EGR1-positive cells in a microscopy field (200× in magnification). EGR1- and KRT18-positive (+) NSCLC cells were defined by the observation of three or more signs (+++) in a 200× microscopy field, whereas the observation of less than three signs (++/+/−) defined EGR1- and KRT18-negative (−) NSCLC cells.

Cell proliferation assay
------------------------

The effect of EGR1 on cell growth rate was evaluated by seeding A549 cells into 96-well plates at a density of 1 × 10^4^ per well. Cells were incubated for 24 h and then transfected with different vectors. Cell growth rate was determined by WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) assay using a cell counting kit-8 (Dojindo Molecular Technologies, Inc., JAPAN) according to the manufacturer\'s instructions. Triplicate independent experiments were conducted.

Cell migration assay
--------------------

Cell mobility was assessed by a scratch wound-healing assay. Briefly, six-well plates were seeded with H1299 or A549 cells, which were transfected with an empty vector or a vector containing EGR1 or dnEGR1 sequence, respectively. Transfected cells were grown to form a confluent monolayer for 24 h and then were mechanically scratched with a sterile pipette tip. The cells were rinsed with PBS and maintained with serum-free medium. Images of the cells were captured after 72 h of culture. The assays were performed in triplicate and repeated at least three times.In migration assay, cells (5 × 10^4^) were suspended in a 500 μl serum-free medium and then seeded in the upper chambers of a Transwell plate (BD Biosciences, USA), whereas the lower chambers were filled with DMEM containing 10% FBS. The cells were incubated for 48 h, after which the plates were fixed and stained using a DiffQuick staining kit (Fisher Scientific Inc.). The cells that migrated toward the bottom surface were counted. Migration rate was determined by counting the number of cells in four high-power fields. The experiments were conducted in triplicate and repeated at least three times.

Western blot
------------

Western blot was performed on 2 × 10^6^ transient recombinant cells according to the general protocol. The primary antibodies for detecting EGR1, caspase-3, and caspase-7 were all purchased from Cell Signaling Technology and diluted at 1∶3000. The antibody for the housekeeping protein β-actin was obtained from Sigma and was diluted at 1∶5000. Chemiluminescence was detected using ECL western blot detection reagents (Pierce, USA).

DNA microarray
--------------

DNA microarray analysis of gene expression was performed by Gene Tech Company Ltd., Shanghai, China. Cells transfected with an empty vector or with pcDNA-EGR1 plasmid were solubilized and homogenized in TRIzol (Invitrogen, Carlsbad, CA). Total RNA was isolated according to the manufacturer\'s instructions, and integrity was tested. Once isolated, mRNA was used as a template for cDNA generation using reverse transcriptase. Affymetrix GeneChip PrimeView™ GeneChip (Affymetrix) covering 48937 transcripts and variants was used to identify differentially expressed genes between H1299 cells transfected with empty vectors and with pcDNA-EGR1 plasmids. Microarray reaction was completed according to the manufacturer\'s instructions. Briefly, 2 μg of pooled total RNA was reversed-transcribed, labeled, and hybridized to the chip at 42°C for 16 h. The chip was washed, scanned, and then visualized with a GeneArray scanner (Hewlett-Packard). Probe set intensities were calculated using the Microarray Analysis Suite (MAS v5.0, Affymetrix) software and normalized against 100 housekeeping genes to a mean intensity of 36,000 in mask files of PrimeView™ GeneChip before further statistical analysis. Normalized expression values were then compared. Fold-change differences were calculated to identify the upregulated and downregulated genes. Transcripts with more than a 2.0-fold difference in expression level were defined as differentially expressed. Specifically designed online tools, including David bioinformatics resource[@b37] and Ingenuity system analysis (IPA)[@b38], were used to classify the functions of the identified differentially expressed genes.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS and GraphPad Prism 5 software. Data were expressed as mean ± SD from at least three independent determinations. Significance of data was analyzed by Student\'s *t*-test. The correlation between EGR1 or KRT18 and clinicopathological characteristics was analyzed by Fisher\'s exact test. Bio-function enrichment profiles from the IPA analysis were used for Fisher\'s exact test. Differences were considered significant at P \< 0.05.
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![Upregulation of EGR1 decreases NSCLC proliferation in vitro.\
(A) Total cell lysates from MRC5 and other indicated NSCLC cell lines were immunoblotted with anti-EGR1. β-actin was used as loading control. (B) Representative of H1299 cells with or without overexpressed EGR1 immunofluorescence-stained with antibodies against EGR1 (red color). The nuclei were counterstained with DAPI (blue color). (C) The growth of H1299 cells infected with CD513B-1-EGR1 or -dnEGR1 was analyzed by CCK8 assay. Up panel: western blot for EGR1 expression levels in H1299 cells transfected with EGR1 or dnEGR1. (D) Histogram showing the percentages of apoptotic cells by flow cytometric staining with Annexin V-PE/7-AAD. (E) Western blot for apoptotic caspase-3 and -7 in H1299 cells with increasing quantities of EGR1 compared with control. Numbers presented the fold change compared with the vector. Relative values ± SD were obtained from three independent assays. The full-length blots of Fig. 1A, 1C and 1E were presented in [Supplementary Fig. S1, S3 and S4](#s1){ref-type="supplementary-material"}.](srep05416-f1){#f1}

![EGR1 decreases cell mobility and migration.\
(A) The effect of EGR1 on cell migration was determined by wound healing assay. The spreading speed of EGR1-transfected cells along the wound edge was slower than that of vector- or dnEGR1-transfected cells over a period of 72 h. (C) Representative images showing the transfected cells that migrated through the cell. The number of migrated tumor cells was quantified and is shown in the right panel. Columns, mean of triplicate experiments; \*P \< 0.05.](srep05416-f2){#f2}

![mRNA expression profile of cells with re-expressed EGR1.\
(A and B) Hierarchical clustering of 100 genes that exhibited significantly altered expression in EGR1-transfected H1299 cells as compared with vector-transfected H1299 cells. The color bar indicates the fold change (log~2~). (C) IPA launch of bio-function enrichment profiles, plotted by relative statistical significance. P value, Fisher\'s exact test. (D) The expression of 15 upregulated genes (ARC, GDF15, CDKN1C, TGM2, HES1, EFNA1, NR4A1, TRIB1, IGFBP6, ITGB8, PDGFA, KRT18, TIMP1, and ID2) was analyzed by qPCR. Relative values ± SD were obtained from three independent assays.](srep05416-f3){#f3}

![KRT18 is a downstream target of EGR1.\
(A) Luciferase reporter assays of sequential deletions of the KRT18 promoter, cotransfected with increasing quantities of EGR1. The predicted positions of the EBS (black boxes) were indicated on the schematic. Nucleotides with red colors presented consensus EBS. Values are expressed as mean fold-activation to the promoter cotransfected with empty vector. (B) Luciferase reporter assays of point mutant of the KRT18 promoter. The consensus EBS in pGL3-KRT18 was mutated, creating pGL3-KRT18-mut. Relative reporter activity in response to EGR1 transfection was compared as in (A). (C) EGR1 and KRT18 protein levels after treatment with different si-EGR1 doses or NC (negative control). β-actin was used as loading control. Values are presented as fold change relative to NC. The full-length blot of Fig. 4C is presented in [Supplementary Fig. S5](#s1){ref-type="supplementary-material"}.](srep05416-f4){#f4}

![KRT18 is able to decrease the malignancy of NSCLC.\
(A) The growth of H1299 and A549 cells infected with CD513B-1-KRT18 was analyzed by CCK-8 assay. The results are expressed as mean ± SD of three independent experiments. (B) The effect of EGR1 on cell migration was determined by wound healing assay. (C) Representative images showing the transfected cells that migrated through the cell. The number of migrated tumor cells was quantified as in [Fig. 2B](#f2){ref-type="fig"}. (D) Western blot for apoptotic caspase-3 and -7 in H1299 cells with different KRT18 transfected dose as compared with control cells. β-actin was used as loading control. The full-length blot of Figure 5D is presented in [Supplementary Fig. S6](#s1){ref-type="supplementary-material"}. (E) Expression level of EGR1 and KRT18 in 2 primary NSCLC cases. (F) Correlation of the EGR1 (+) expression with age, lymph node metastasis and KRT18 in 36 NSCLC cases. (G) Correlation of the KRT18 (+) expression with lymph node metastasis in 36 NSCLC cases.](srep05416-f5){#f5}

###### Genes differentially expressed between EGR1-overexpressed H1299 cells and control cells

  Gene Symbol                                                                   Gene Title                                         Fold-Change    Probe Set ID    Entrez Gene
  --------------------------------------- --------------------------------------------------------------------------------------- ------------- ---------------- -------------
  **Cellular Growth and Proliferation**                                                                                                                                 
  ***Upregulated genes***                                                                                                                                               
  MGP                                                                       Matrix Gla protein                                        9.75       11716203_a\_at      4256
  CDKN1C                                                     Cyclin-dependent kinase inhibitor 1C (p57, Kip2)                         9.07       11763717_a\_at      1028
  GDF15                                                              Growth differentiation factor 15                                 7.83       11716663_a\_at      9518
  SERPINA1                                  Serpin peptidase inhibitor, clade A (alpha-1 Antiproteinase, antitrypsin), member 1       4.42       11721455_s\_at      5265
  ITGB8                                                                      Integrin, beta 8                                         4.32        11722503_at        3696
  HEY1                                                       Hairy/enhancer-of-split related with YRPW motif 1                        4.14        11718201_at        23462
  IL11                                                                        Interleukin 11                                          3.92        11727690_at        3589
  FGFR3                                                             Fibroblast growth factor receptor 3                               3.83       11755786_a\_at      2261
  NR4A1                                                       Nuclear receptor subfamily 4, group A, member 1                         3.74       11717994_a\_at      3164
  ID2                                             Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein              3.68       11715994_x\_at      3398
  KRT8                                                                           keratin 8                                            3.54       11756989_x\_at      3856
  KRT18                                                                         keratin 18                                            3.39       11757905_x\_at      3875
  TGM2                                        Transglutaminase 2 (C polypeptide, protein-glutamine-Gamma-glutamyltransferase)         3.29       11718399_s\_at      7052
  IER3                                                                  Immediate early response 3                                    2.99       11720062_s\_at      8870
  ITGA7                                                                      Integrin, alpha 7                                        2.86       11718243_a\_at      3679
  CD24                                                                         CD24 molecule                                          2.78       11715918_s\_at     1E + 08
  TRIB1                                                               Tribbles homolog 1 (Drosophila)                                 2.72        11716048_at        10221
  RASD1                                                                RAS, dexamethasone-induced 1                                   2.68       11716839_a\_at      51655
  RAPGEF3                                                     Rap guanine nucleotide exchange factor (GEF) 3                          2.68        11760609_at        10411
  TIMP1                                                              TIMP metallopeptidase inhibitor 1                                2.62       11715360_x\_at      7076
  SERPINB2                                               Serpin peptidase inhibitor, clade B (ovalbumin), member 2                    2.53       11716631_s\_at      5055
  VEGFA                                                            Vascular endothelial growth factor A                               2.51       11738414_a\_at      7422
  FBXO2                                                                       F-box protein 2                                         2.51        11722236_at        26232
  HES1                                                         Hairy and enhancer of split 1, (*Drosophila*)                          2.42       11716551_s\_at      3280
  HEYL                                                     Hairy/enhancer-of-split related with YRPW motif-like                       2.28       11722074_s\_at      26508
  CAMK2N1                                               Calcium/calmodulin-dependent protein kinase II inhibitor 1                    2.25       11719242_s\_at      55450
  NPTX2                                                                    Neuronal pentraxin II                                      2.24        11720005_at        4885
  EFNA1                                                                          Ephrin-A1                                            2.21       11716341_s\_at      1942
  IGFBP6                                                       Insulin-like growth factor binding protein 6                           2.21        11717909_at        3489
  PDGFA                                                      Platelet-derived growth factor alpha polypeptide                         2.19       11729062_a\_at      5154
  GADD45B                                                      Growth arrest and DNA-damage-inducible, beta                           2.18       11757865_a\_at      4616
  DDIT3                                                              DNA-damage-inducible transcript 3                                2.17       11758198_s\_at      1649
  SERTAD1                                                                SERTA domain containing 1                                    2.15        11718631_at        29950
  FOS                                                         FBJ murine osteosarcoma viral oncogene homolog                          2.15       11734659_a\_at      2353
  MMP9                                     Matrix metallopeptidase 9 (gelatinase B, 92kDa Gelatinase, 92kDa type IV collagenase)      2.13       11719657_a\_at      4318
  GNG7                                                    Guanine nucleotide binding protein (G protein), gamma 7                     2.11       11723239_a\_at      2788
  LIF                                                 Leukemia inhibitory factor (cholinergic differentiation factor)                 2.10       11758619_s\_at      3976
  KCTD11                                                  Potassium channel tetramerisation domain containing 11                      2.09        11725178_at       147040
  FST                                                                           Follistatin                                           2.08        11732713_at        10468
  LEF1                                                              Lymphoid enhancer-binding factor 1                                2.03       11726333_s\_at      51176
  ***Downregulated genes***                                                                                                                                             
  PRKDC                                                    Protein kinase, DNA-activated, catalytic polypeptide                       −2.97      11719391_a\_at      5591
  PUS7L                                                   Pseudouridylate synthase 7 homolog (S. cerevisiae)-like                     −2.81      11727136_a\_at      83448
  TOP1                                                                     Topoisomerase (DNA) I                                      −2.51      11717437_x\_at      7150
  CDC27                                                       Cell division cycle 27 homolog (S. cerevisiae)                          −2.22      11743401_x\_at       996
  PPP1R1C                                                Protein phosphatase 1, regulatory (inhibitor) subunit 1C                     −2.04      11763834_a\_at     151242
  **Cellular movement**                                                                                                                                                 
  ***Upregulated genes***                                                                                                                                               
  MGP                                                                       Matrix Gla protein                                        9.75       11716203_a\_at      4256
  GDF15                                                              Growth differentiation factor 15                                 7.83       11716663_a\_at      9518
  NPTX1                                                                    Neuronal pentraxin I                                       7.50       11755325_s\_at      4884
  SERPINA1                                  Serpin peptidase inhibitor, clade A (alpha-1 Antiproteinase, antitrypsin), member 1       4.42       11721455_s\_at      5265
  ITGB8                                                                      Integrin, beta 8                                         4.32        11722503_at        3696
  HEY1                                                       Hairy/enhancer-of-split related with YRPW motif 1                        4.14        11718201_at        23462
  IL11                                                                        Interleukin 11                                          3.92        11727690_at        3589
  NR4A1                                                       Nuclear receptor subfamily 4, group A, member 1                         3.74       11717994_a\_at      3164
  ID2                                             Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein              3.68       11715994_x\_at      3398
  TGM2                                        Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)         3.29       11718399_s\_at      7052
  IER3                                                                  Immediate early response 3                                    2.99       11720062_s\_at      8870
  CD24                                                                         CD24 molecule                                          2.78       11715918_s\_at     1E + 08
  TRIB1                                                               Tribbles homolog 1 (Drosophila)                                 2.72        11716048_at        10221
  RAPGEF3                                                     Rap guanine nucleotide exchange factor (GEF) 3                          2.68        11760609_at        10411
  TIMP1                                                              TIMP metallopeptidase inhibitor 1                                2.62       11715360_x\_at      7076
  SERPINB2                                               Serpin peptidase inhibitor, clade B (ovalbumin), member 2                    2.53       11716631_s\_at      5055
  VEGFA                                                            Vascular endothelial growth factor A                               2.51       11738414_a\_at      7422
  NPTX2                                                                    Neuronal pentraxin II                                      2.24        11720005_at        4885
  EFNA1                                                                          Ephrin-A1                                            2.21       11716341_s\_at      1942
  IGFBP6                                                       Insulin-like growth factor binding protein 6                           2.21        11717909_at        3489
  PDGFA                                                      Platelet-derived growth factor alpha polypeptide                         2.19       11729062_a\_at      5154
  FOS                                                         FBJ murine osteosarcoma viral oncogene homolog                          2.15       11734659_a\_at      2353
  MMP9                                     Matrix metallopeptidase 9 (gelatinase B, 92kDa Gelatinase, 92kDa type IV collagenase)      2.13       11719657_a\_at      4318
  LIF                                                 Leukemia inhibitory factor (cholinergic differentiation factor)                 2.10       11758619_s\_at      3976
  FST                                                                           Follistatin                                           2.08        11732713_at        10468
  LEF1                                                              Lymphoid enhancer-binding factor 1                                2.03       11726333_s\_at      51176
  S100A2                                                              S100 calcium binding protein A2                                 2.04        11718779_at        6273
  **Downregulated genes**                                                                                                                                               
  DEK                                                                          DEK oncogene                                           −2.00      11743653_x\_at      7913
  **Gene expression**                                                                                                                                                   
  **Upregulated genes**                                                                                                                                                 
  CDKN1C                                                     Cyclin-dependent kinase inhibitor 1C (p57, Kip2)                         9.07       11763717_a\_at      1028
  HEY1                                                       Hairy/enhancer-of-split related with YRPW motif 1                        4.14        11718201_at        23462
  SOX8                                                             SRY (sex determining region Y)-box 8                               4.00        11721911_at        30812
  IL11                                                                        interleukin 11                                          3.92        11727690_at        3589
  NR4A1                                                       Nuclear receptor subfamily 4, group A, member 1                         3.74       11717994_a\_at      3164
  ID2                                             Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein              3.68       11715994_x\_at      3398
  TGM2                                        Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)         3.29       11718399_s\_at      7052
  IER3                                                                  Immediate early response 3                                    2.99       11720062_s\_at      8870
  ID4                                             Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein              2.62        11721687_at        3400
  TIMP1                                                              TIMP metallopeptidase inhibitor 1                                2.62       11715360_x\_at      7076
  VEGFA                                                            Vascular endothelial growth factor A                               2.51       11738414_a\_at      7422
  HES1                                                          Hairy and enhancer of split 1, (Drosophila)                           2.42       11716551_s\_at      3280
  HEYL                                                     Hairy/enhancer-of-split related with YRPW motif-like                       2.28       11722074_s\_at      26508
  PDGFA                                                      Platelet-derived growth factor alpha polypeptide                         2.19       11729062_a\_at      5154
  DDIT3                                                              DNA-damage-inducible transcript 3                                2.17       11758198_s\_at      1649
  FOS                                                         FBJ murine osteosarcoma viral oncogene homolog                          2.15       11734659_a\_at      2353
  LIF                                                 Leukemia inhibitory factor (cholinergic differentiation factor)                 2.10       11758619_s\_at      3976
  FST                                                                           follistatin                                           2.08        11732713_at        10468
  LEF1                                                              Lymphoid enhancer-binding factor 1                                2.03       11726333_s\_at      51176
  ***Downregulated genes***                                                                                                                                             
  PRKDC                                                    Protein kinase, DNA-activated, catalytic polypeptide                       −2.97      11719391_a\_at      5591
  TOP1                                                                     Topoisomerase (DNA) I                                      −2.51      11717437_x\_at      7150
  ACTR2                                                        ARP2 actin-related protein 2 homolog (yeast)                           −2.08      11739033_a\_at      10097
  DEK                                                                          DEK oncogene                                           −2.00      11743653_x\_at      7913
  CENPF                                                         Centromere protein F, 350/400kDa (mitosin)                            −2.00      11743295_a\_at      1063
